Sensus Healthcare (NASDAQ:SRTS – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01), Zacks reports. Sensus Healthcare had a net margin of 22.54% and a return on equity of 17.99%.
Sensus Healthcare Trading Up 6.5 %
NASDAQ SRTS traded up $0.55 on Wednesday, hitting $8.99. 702,035 shares of the company were exchanged, compared to its average volume of 266,379. The company has a market cap of $147.35 million, a P/E ratio of 15.77 and a beta of 1.24. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33. The firm has a 50 day moving average of $7.48 and a two-hundred day moving average of $6.88.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on SRTS. Lake Street Capital started coverage on shares of Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock. Maxim Group upped their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, HC Wainwright lifted their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th.
About Sensus Healthcare
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also
- Five stocks we like better than Sensus Healthcare
- How to Invest in Biotech Stocks
- 3 Must-Have ETFs Set to Dominate This Quarter
- Business Services Stocks Investing
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.